CIRM provides funding across five key areas: Infrastructure, Education, Discovery Research, Translational Research, and Clinical Research. By supporting projects at every stage of development, from initial discovery to clinical trials, CIRM drives progress in regenerative medicine and accelerates innovative therapies to patients.
Check out our portfolio of awards below. Click here to see a list of People We’ve Funded. Click here to see a list of our Funded Institutions.
All CIRM Grants
Search Filters »
| Institution |
Researcher name |
Grant Type |
Grant Title |
Award Value |
| University of California, Los Angeles |
Dr. Sophie X Deng |
Clinical Trial Stage Projects |
Safety and Feasibility of Cultivated Autologous Limbal Stem Cells for Limbal Stem Cell Deficiency |
$10,301,486 |
| City of Hope, Beckman Research Institute |
Dr Jana Portnow |
Clinical Trial Stage Projects |
A Phase I Study of Chimeric Antigen Receptor Engineered Stem/Memory T Cells for the Treatment of HER2-Positive Brain Metastases |
$8,090,000 |
| Cedars-Sinai Medical Center |
Professor Clive Niels Svendsen |
Clinical Trial Stage Projects |
Clinical Study to Assess Safety and Efficacy of Subretinal Injection of Human Neural Progenitor Cells for Treatment of Retinitis Pigmentosa |
$10,444,063 |
| University of California, San Diego |
Dr. Stephanie Cherqui |
Clinical Trial Stage Projects |
Phase 1/2 study for autologous human CD34+ hematopoietic stem cells ex vivo transduced with pCCL-CTNS lentiviral vector for treatment of Cystinosis. |
$11,999,944 |
| University of California, San Francisco |
Peter Stock |
Clinical Trial Stage Projects |
Pancreatic Islets and Parathyroid Gland Co-transplantation for Treatment of Diabetes in the Intra-Muscular Site: PARADIGM |
$7,913,768 |
| Jasper Therapeutics, Inc. |
Wendy Pang |
Clinical Trial Stage Projects |
A monoclonal antibody that depletes blood stem cells and enables chemotherapy free transplants |
$2,313,398 |
| Stanford University |
Dr. Everett H. Meyer |
Clinical Trial Stage Projects |
Induction of Tolerance by Combinatorial Therapy w/ Donor Stem Cells and Expanded Recipient Treg cells in HLA-mismatched Kidney Transplant Recipients |
$8,920,000 |
| Children’s Hospital of Los Angeles |
Michael A. Pulsipher |
Clinical Trial Stage Projects |
Antiviral Cellular Therapy for Enhancing T-cell Reconstitution Before or After Hematopoietic Stem Cell Transplantation (ACES) |
$4,825,587 |
| Stanford University |
Dr Robert Lowsky |
Clinical Trial Stage Projects |
Induction of Tolerance to Combined Kidney and Hematopoietic Progenitor Cell Transplants from HLA Haplotype Matched Living Donors |
$6,653,266 |
| University of California, Los Angeles |
Dr. Donald B. Kohn |
Clinical Trial Stage Projects |
Efficacy and safety of cryopreserved autologous CD34+ HSC transduced with EFS lentiviral vector encoding for human ADA gene in ADA-SCID subjects |
$5,827,000 |
| Cure Rare Disease |
Dr. Susan Perlman |
Late Stage Preclinical Projects |
Advancing a novel antisense oligonucleotide for the treatment of SCA3, a devastating neurodegenerative disease |
$5,692,538 |
| University of California, Davis |
Dr. Joseph S Anderson |
Late Stage Preclinical Projects |
Expression of Ube3a by the hematopoietic system for the treatment of Angelman syndrome |
$4,487,656 |
| Rejuvenate Bio |
Noah Davidsohn |
Late Stage Preclinical Projects |
Novel Gene Therapy Targeting Multiple Pathological Drivers of Desmoplakin Associated Arrhythmogenic Cardiomyopathy |
$570,000 |
| Amplo Biotechnology Inc |
Patricio Sepulveda |
Late Stage Preclinical Projects |
Targeted DOK7 gene therapy for Congenital Myasthenic Syndromes |
$2,894,305 |
| University of California, San Diego |
Mark H Tuszynski |
Late Stage Preclinical Projects |
Human Embryonic Stem Cell-Derived Neural Stem Cells for Severe Spinal Cord Injury (SCI) |
$6,000,000 |
| University of California, Los Angeles |
Dr. Arjun Deb |
Late Stage Preclinical Projects |
Development of a therapeutic monoclonal antibody for the treatment of myocardial infarction and heart failure |
$5,999,998 |
| Children’s Hospital of Los Angeles |
Shahab Asgharzadeh |
Late Stage Preclinical Projects |
Chimeric TGFB Signaling Receptor (CTSR) Enabled Anti-B7H3 CAR T-cell Therapy in Children and AYA with Recurrent Solid Tumors |
$6,000,000 |
| University of California, San Francisco |
Thomas Martin |
Late Stage Preclinical Projects |
A 1XX-enhanced and fully non-viral BCMA CAR T cell therapy for Relapsed and Refractory Multiple Myeloma (UCCT-BCMA-1) |
$4,585,501 |
| Elpida Therapeutics |
Mr Terry Pirovolakis |
Late Stage Preclinical Projects |
Pre-Clinical To Clinical Gene Therapy Development For CMT4J |
$3,930,964 |
| Cedars-Sinai Medical Center |
Dr. Eugenio Cingolani |
Late Stage Preclinical Projects |
Extracellular Vesicles for Ventricular Tachycardia |
$5,999,441 |
| City of Hope, Beckman Research Institute |
Prof. Karen S Aboody M.D. |
Late Stage Preclinical Projects |
Neural stem cell delivered CRAd-S-pk7 oncolytic viro-immunotherapy for ovarian cancer |
$5,314,547 |
| Mahzi Therapeutics |
Dr. Yael Weiss |
Late Stage Preclinical Projects |
Development of a Gene Therapy for the Treatment of WWOX related epileptic encephalopathy (WOREE) |
$4,000,000 |
| University of California, Davis |
Dr Mehrdad Abedi |
Late Stage Preclinical Projects |
Superior forward-oriented b-globin vector for treating Sickle Cell Disease |
$4,598,398 |
| Stanford University |
Dr. Matthew H Porteus |
Late Stage Preclinical Projects |
Autologous Gene Corrected Sinus Basal Cells to Treat Serious Cystic Fibrosis Sinus Disease |
$6,000,000 |
| University of California, Irvine |
Kyriacos A Athanasiou |
Late Stage Preclinical Projects |
Treatment of the TMJ disc complex |
$6,000,000 |
| University of Southern California |
Dr. Mark S Humayun |
Late Stage Preclinical Projects |
IND-enabling program for PRPE-SF, the secretome from polarized stem cell-derived RPE cells, for the treatment of dry-age related macular degeneration |
$5,993,562 |
| Aspera Biomedicines, Inc. |
Catriona Jamieson |
Late Stage Preclinical Projects |
Cancer Stem Cell Interception with Rebecsinib: A First-in-Class ADAR1 Inhibitor |
$3,200,000 |
| University of California, Los Angeles |
Dr. Jerome A. Zack Ph.D. |
Late Stage Preclinical Projects |
Clinical Translation of Autologous Regenerative Pluripotent Stem Cell Therapy for Blindness |
$6,000,000 |
| Rampart Bioscience |
Jeffrey Bartlett |
Late Stage Preclinical Projects |
Ex vivo Engineering of Autologous Hematopoietic Stem Cells for the Treatment of Hypophosphatasia |
$3,999,980 |
| Calidi Biotherapeutics, Inc. |
8587949607 Boris Minev |
Late Stage Preclinical Projects |
Allogeneic mesenchymal stem cells loaded with oncolytic virus for cancer treatment |
$3,111,467 |
| Ossium Health, Inc. |
Dr. Brian Johnstone |
Late Stage Preclinical Projects |
Development of OSSM-007, cryopreserved interferon-gamma primed allogeneic MSCs, for treatment of steroid refractory acute graft versus host disease |
$3,457,858 |
| University of California, Davis |
Dr. Joseph S Anderson |
Late Stage Preclinical Projects |
Hematopoetic stem cell gene therapy for the treatment of Tay-Sachs disease |
$4,048,253 |
| Stanford University |
Natalia Gomez-Ospina |
Late Stage Preclinical Projects |
Genome Editing of Autologous Hematopoietic Stem Cells to Treat Severe Mucopolysaccharidosis type 1 (Hurler Syndrome) |
$5,444,353 |
| University of California, San Francisco |
Dr. Karin Lindgren Gaensler |
Late Stage Preclinical Projects |
Development of TriLeukeVax, an Engineered Autologous Leukemia Vaccine for Stimulating Cytolytic Immune Responses to Residual Leukemic Stem Cells |
$6,000,000 |
| ImmunoVec |
Dr. Ryan L. Wong |
Late Stage Preclinical Projects |
Hematopoietic Stem Cell Gene Therapy for XCGD |
$3,999,959 |
| University of California, Los Angeles |
Dr. Antoni Ribas MD/PhD |
Late Stage Preclinical Projects |
Skin regeneration and wound healing with a topical BRAF inhibitor |
$5,005,126 |
| University of Southern California |
Dr. Denis A Evseenko Dr. |
Late Stage Preclinical Projects |
Plurocart: a novel stem cell-based implant for articular cartilage restoration |
$5,999,782 |
| University of California, Irvine |
Dr. Leslie M Thompson |
Late Stage Preclinical Projects |
An hESC-derived hNSC Therapeutic for Huntington’s Disease |
$5,635,393 |
| University of California, Los Angeles |
Dr. Donald B. Kohn |
Disease Team Therapy Development III |
Clinical Trial of Stem Cell Gene Therapy for Sickle Cell Disease |
$10,351,535 |
| Solano Community College |
James DeKloe |
COMPASS Training Grant |
IDEA-CBMS – Increase Diversity, Equity, and Advancement in Cell Based Manufacturing Sciences |
$2,894,500 |
| University of Southern California |
Dr. Senta Georgia |
COMPASS Training Grant |
USC COMPASS: Guiding Undergraduates to Careers in Regenerative Medicine |
$2,899,999 |
| University of California, Berkeley |
John Matsui |
COMPASS Training Grant |
The COMPASS Scholars Program – Developing Today’s Untapped Talent into Tomorrow’s STEM Cell Researchers |
$2,889,750 |
| University of California, Los Angeles |
Tracy L Johnson |
COMPASS Training Grant |
COMPASS: Accelerating Stem Cell Research by Educating and Empowering New Stem Cell Researchers |
$2,910,000 |
| University of California, Santa Barbara |
Dr. Dennis O. Clegg Dr. |
COMPASS Training Grant |
Training and mentorship program in stem cell biology and engineering: A COMPASS for the future |
$2,746,000 |
| Cal Poly Corporation, an Auxiliary of California Polytechnic State University, San Luis Obispo |
Dr. Kristen OHalloran Cardinal |
COMPASS Training Grant |
A COMPASS to guide the growth of a diverse regenerative medicine workforce that represents California and benefits the world |
$2,887,939 |
| University of California, Merced |
Dr. Kara E McCloskey |
COMPASS Training Grant |
Training Undergraduates in Stem Cell Engineering and Biology (TUSCEB) |
$2,909,999 |
| San Francisco State University |
Dr. Lily Chen |
COMPASS Training Grant |
Inclusive Pathways for a Stem Cell Scholar (iPSCS) Undergraduate Training Program |
$2,894,500 |
| California State University San Marcos Corporation |
Dr. Bianca Romina Mothé |
COMPASS Training Grant |
COMPASS Program for Southern California Hispanic Serving Institution |
$2,786,300 |
| The University Corporation at California State University, Northridge |
Cindy S Malone |
COMPASS Training Grant |
CSUN CIRM COMPASS Training Program (N-COMPASS) |
$2,746,805 |
| Cal State Univ, San Bernadino |
Daniel Nickerson |
COMPASS Training Grant |
Student Pluripotency: Realizing Untapped Undergraduate Potential in Regenerative Medicine |
$2,909,853 |
